Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other solid neoplasm 2

Conditions

Lymphoma 3Solid Tumors 2Neoplasms 2Lymphoma, T-Cell, Peripheral 2Sarcoma 1Recurrence 1Neoplasm Metastasis 1Myeloproliferative Disorders 1Multiple Myeloma 1Leukemia 1Hematologic Neoplasms 1Carcinoma 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Paclitaxel 12Gemcitabine 9atezolizumab 8Carboplatin 8Bevacizumab 6tocilizumab 4navitoclax 4liposomal doxorubicin 4Irinotecan 4Erlotinib Hydrochloride 4Cetuximab 4Sunitinib 3Oxaliplatin 3Leucovorin 3Injections 3Fluorouracil 3Docetaxel 3Cyclophosphamide 3tumor necrosis factor-alpha, CNGRC fusion protein, human 2tislelizumab 2temsirolimus 2ridaforolimus 2plocabulin 2pembrolizumab 2pazopanib 2olaparib 2obinutuzumab 2linifanib 2fludarabine 2envafolimab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Solid Tumors × darinaparsin × Clear all
NCT00509782 2012-08-01

Phase I Trial of ZIO-101 in Patients With Solid Tumors

M.D. Anderson Cancer Center

Phase 1 Completed
47 enrolled
Other solid neoplasm

Solid Tumors

NCT00591396 2012-07-19

A Phase I Trial of ZIO-101 in Solid Tumors

Alaunos Therapeutics

Phase 1 Completed
40 enrolled
Other solid neoplasm

Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡